Dechert LLP advised Selvita S.A., an international drug discovery company with extensive experience in the life sciences sector, on the launch of Nodthera Limited, a new biotech company launched by Epidarex Capital based on research by Selvita. Nodthera Limited, headquartered in Edinburgh, Scotland, will focus on the discovery and development of novel inhibitors of the NLRP3 inflammasome.

The Frankfurt-based Dechert team advising Selvita was led by corporate national partner Jochen Eimer, with assistance from partner Dr. Rüdiger Herrmann and international counsel Alicia Hong.